Publications by authors named "Matthew W Jenner"

Claim this Profile
E
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter M Voorhees, Matthew W Jenner

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Martin F Kaiser, Andrew Hall, Katrina Walker, Amy Sherborne, Ruth M De Tute, Matthew W Jenner

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
John R Jones, David A Cairns, Tom Menzies, Charlotte Pawlyn, Faith E Davies, Matthew W Jenner

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Sian E Faustini, Andrew Hall, Sarah Brown, Sadie Roberts, Harriet Hill, Matthew W Jenner

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Matthew W Jenner, Charlotte Pawlyn, Faith E Davies, Tom Menzies, Anna Hockaday

Br J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Ruth M de Tute, Charlotte Pawlyn, David A Cairns, Faith E Davies, Tom Menzies, Matthew W Jenner

J Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Matthew W Jenner

Haematologica· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
James Croft, Sidra Ellis, Amy L Sherborne, Kim Sharp, Amy Price, Matthew W Jenner

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Nadjoua Maouche, Bhuvan Kishore, Matthew W Jenner, Kevin Boyd, Zara Bhatti

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Graham H Jackson, Charlotte Pawlyn, David A Cairns, Alina Striha, Corinne Collett, Matthew W Jenner

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Sarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, Debbie Sherratt, Louise Flanagan, Matthew W Jenner

Clin Lymphoma Myeloma Leuk· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Graham H Jackson, Charlotte Pawlyn, David A Cairns, Ruth M de Tute, Anna Hockaday, Matthew W Jenner

PLoS Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Vallari Shah, Amy L Sherborne, David C Johnson, Sidra Ellis, Amy Price, Matthew W Jenner

Leukemia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Charlotte A Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A Cairns, Matthew W Jenner

Blood· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
Jagrati Chopra, Hwai J Hiew, Andrew Cumpstey, Felino Cagampang, Matthew W Jenner

Br J Haematol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
C Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter Voorhees, Matthew W Jenner

Leukemia· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiri Minarik, Ioannis Ntanasis-Stathopoulos, Matthew W Jenner

Ann Hematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Matthew W Jenner

Lancet Haematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Matthew W Jenner

Lancet Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subclonal copy number is associated with prognosis in multiple myeloma.
Vallari Shah, David C Johnson, Amy L Sherborne, Sidra Ellis, Frances M Aldridge, Matthew W Jenner

Blood· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
Katy J McCann, Rosemary Godeseth, Lindsey Chudley, Ann Mander, Gianfranco Di Genova, Matthew W Jenner

Cancer Immunol Immunother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Amy Publicover, Deborah S Richardson, Andrew Davies, Kate S Hill, Carol Hurlock, Matthew W Jenner

Br J Haematol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
Brian A Walker, Paola E Leone, Laura Chiecchio, Nicholas J Dickens, Matthew W Jenner

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
Nicholas J Dickens, Brian A Walker, Paola E Leone, David C Johnson, José L Brito, Matthew W Jenner

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Paola E Leone, Brian A Walker, Matthew W Jenner, Laura Chiecchio, Gianpaolo Dagrada

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis